Biological assets

Joinn Laboratories, China’s leading non-clinical contract research organization (CRO), announced on Monday its revenue rose 15.1% to 575 million yuan in the third quarter.

FAST NEWS: Joinn Lab profit slumps on falling lab monkey prices

The latest: Joinn Laboratories (China) Co. Ltd. (6127.HK; 603127.SH), China’s leading non-clinical contract research organization (CRO), announced on Monday its revenue rose 15.1% to 575 million yuan ($78.6 million) in the third quarter,…
6127.HK 603127.SHG

Joinn profits slide as lab monkey build-up backfires

The leading provider of pre-clinical drug research has predicted its first-half profits will plummet between 70% and 80% due to the falling value of its lab animals Key Takeaways: Joinn…
6127.HK 603127.SHG

Recent Articles

RELATED ARTICLES

  1. During the Covid pandemic, lab monkeys that are one of Joinn’s main businesses were in short supply as companies rushed to develop Covid vaccines and drugs.
    FAST NEWS: Joinn Lab swings to the red on falling revenue
    6127.HK 603127.SHG
  2. FAST NEWS: Joinn Laboratories spents $3.7 million on share buyback
    6127.HK 603127.SHG
  3. Goldwind’s profit tumbles as China sales start to deflate
    2208.HK 002202.SHE
  4. Test results for new cancer drug take Akeso investors on wild ride
    9926.HK
  5. Akeso marks profit milestone with swift rights issue
    9926.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva